Biocardia Inc is a biotechnology company focused on developing innovative regenerative medicine therapies for heart disease and other cardiovascular conditions
The company is engaged in the research and development of cell-based and cellular therapies, leveraging advanced technologies to create treatments aimed at improving heart function and overall patient outcomes. Through its proprietary platforms, Biocardia seeks to address unmet medical needs in the field of cardiology, with the goal of enhancing the standard of care for patients suffering from chronic heart ailments.
BioCardia shares are trading higher by 95% during Thursday's session. The FDA cleared the company to market its Morph DNA Steerable Introducer product family.
On Friday before the market open, BioCardia announced it received approval from the United States Patent Office for its application entitled, "Radial and Transendocardial Delivery Catheter."
